New genes involved in Acute Lymphoblastic Leukemia play fundamental role in prognosis of the disease

February 09, 2009

The inactivity or "silence" of certain genes plays a fundamental role in the prognosis of acute lymphoblastic leukemia (ALL) as well as in response to treatment, according to the results of research involving a team made up of specialists from the University Hospital of Navarra and the Centre for Applied Medical Research (CIMA) at the same University of Navarra, as well as the Reina Sofía Hospital in Córdoba, Andalusia.

In concrete, the work confirmed that the inactivation of 13 microRNAs (a type of gene) by an epigenetic mechanism (capable of modulating the functions of the genetic code), is associated with higher mortality amongst patients with ALL. In total, the study involved 353 patients - 179 children and 174 adults - with acute lymphoblastic leukaemia). The results open up new therapeutic options on demonstrating the possibility of using these microRNAs as new targets in the treatment of this cancer illness. The conclusions of the research were recently published in the scientific journal with the greatest international impact in its speciality, the Journal of Clinical Oncology.

Involved in the research work was a team made up of specialists from the University Hospital of Navarra and the Centre for Applied Medical Research (CIMA) of the University of Navarra. Specialists from the Reina Sofía Hospital in Córdoba and the Institute of Human Genetics at the Schleswig-Holstein University Hospital, Kiel Campus in Germany also participated in the study and the publication of results.

It is notable that acute lymphoblastic leukaemia is the most common oncological illness amongst children. It makes up 25% of all cancers amongst paediatric patients and approximately 75% of cases of leukemia in infancy, although current survival rates in developed countries stand at about 75% of diagnosed patients.
Subgroup with worst prognosis

With this research a set of 13 microRNAs was identified which showed up as epigenetically regulated in 65% of the patients studied with acute lymphoblastic leukaemia, according to Doctor Prósper. Epigenetic regulation is the modulation of the genes expression that does not depend on changes in the sequence of the genetic code and the influence of which in cancer is increasingly being demonstrated. They are, thus, reversible changes in the DNA that manage to get the genes to be expressed or not (to be activated or silent) depending on external conditions.

In the subgroup of patients amongst which this set of genes appears as regulated, it was shown that, although these patients initially responded to treatment, they were the ones who with greater frequency subsequently suffered relapse, disimprove and present the worst prognosis and survival rates. These are the patients amongst whom the disease is much more resistant to treatment and amongst whom a silencing of the expression of the microRNAs is produced, according to the specialist.
Most efficacious pharmaceutical drugs

Given these result, Doctor Prósper concludes that epigenetic regulation plays a fundamental role in the development of this disease. Moreover, he points out, it would seem that the most recent pharmaceutical drugs, capable of producing epigenetic alterations, can be effective in 65% of patients who respond worst to conventional therapies for acute lymphoblastic leukaemia.

Elhuyar Fundazioa

Understanding Acute Lymphoblastic Leukaemia
by CancerBACUP (Author)

Understanding Acute Lymphoblastic Leukaemia
by CancerBACUP (Publisher)

New Agents for the Treatment of Acute Lymphoblastic Leukemia
by Vaskar Saha (Editor), Pamela Kearns (Editor)

The majority of cancers present at a relatively advanced stage in which invasion within the primary organ is well established and metastases to lymph and distant organs are either clinically apparent or present at the microscopic level. However, it is increasingly recognized that the natural history of cancer formation is a long and complex path taking many years to develop to a clinically apparent stage in most cases. Furthermore, for most solid tumours there is a pre-invasive or intraepithelial stage of disease. This affords the opportunity for early detection and prevention of invasive disease and hence a cure. However, with this advancing knowledge comes a whole plethora of questions which will be explored in this monograph. Firstly, we need to understand the global burden of...

Therapeutic efficacy of natural compounds from Viscum album L. in acute lymphoblastic leukaemia.(Report): An article from: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology
by Catharina I. Delebinski (Author), Sebastian Jager (Author), Kristin Kemnitz-Hassani (Author), Gunter Henze (Author), Holger N. Lode (Author), Georg Seifert (Author)

Acute Myelogenous Leukemia (Contemporary Hematology)
by Judith E. Karp (Editor)

This is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. There is an emphasis throughout on the bidirectional flow of knowledge between the clinical and laboratory arenas.

Childhood Leukemia: A Practical Handbook (Pediatric Oncology)
by Gregory H. Reaman (Editor), Franklin O. Smith (Editor)

This book is a comprehensive and up-to-date compendium on all aspects of childhood leukemia. After introductory chapters on the epidemiology and biology of pediatric leukemia, treatment considerations are extensively reviewed, with emphasis on the use of risk-adjusted treatment approaches. Promising targeted agents are discussed, and strategies for the development of new agents are appraised. The late effects of leukemia and its therapy are then considered in depth, with due attention to management of the psychosocial impact of the disease. Finally, global strategies to improve leukemia care and outcome are reviewed, and future directions discussed. The authors are internationally recognized experts and offer a largely evidence-based consensus on etiology, biology, and treatment. This...

Acute Lymphoblastic Leukaemia (UCLA symposia on molecular and cellular biology)
by Robert Peter Gale (Editor), Dieter Hoelzer (Editor)

This volume integrates information ranging from molecular biology to the use of bone marrow transplants in the treatment of acute lymphoblastic leukemia (ALL). Focusing on controversial issues, this volume unites basic research and clinical data in evaluating recent progress and pointing out areas for future investigations in leukemia diagnosis and therapy. Timely studies of oncogenes, retroviruses and chromosome alterations provide important data on the mechanistic and developmental aspects of ALL, in addition to exploring the role of hematopoietic growth factors and lymphokines in cell growth regulation. The volume reviews the development of in vitro assays for the analysis of leukemia cells and recent progress in the treatment of adults and children with ALL.

Myelodysplastic Syndromes & Secondary Acute Myelogenus Leukemia: Directions for the New Millennium (Cancer Treatment and Research)
by Azra Raza (Editor), Suneel D. Mundle (Editor)

Myelodysplastic syndromes are to the bone marrow what pneumonia is to the lungs; the response of an organ to a variety of etiologic insults like aging, toxic exposure, infections and auto-immunity. Among infectious causes alone, pneumonia could be the result of a variety of possible pathogens including bacterial, viral, tuberculous or fungal agents. Similarly, MDS cannot be treated as a single disease. Attempts to harness the inherent complexity of MDS by devising `classifications' which group the various syndromes as one disease is as misguided as saying that a pneumonia is not infectious because it did not respond to antibiotics. Progress in the field will occur faster when we re-analyze this premise. Therefore, until a clearer picture of the disease emerges it is best to...

Management of Hematologic Malignancies
by Susan O'Brien MD (Editor), Julie M. Vose MD (Editor), Hagop M. Kantarjian MD (Editor)

Hematologic malignancies were the first human cancers to be studied in depth at the molecular level, and recent years have seen important advances in treatment. This comprehensive reference book covers the full range of hematologic malignancies, including all subtypes of leukemias, lymphomas, and plasma cell dyscrasias. Authored by internationally known experts, each chapter emphasizes diagnostic work-up, staging, and therapeutic approaches. Up-to-date hematopathology, treatment, and outcomes data are presented in a way which is directly applicable to patient care. Highly illustrated with color images, graphs, flowcharts and treatment algorithms, the book is perfect for quick clinical reference as well as providing detailed reference lists for further study. With its authoritative and...

Chronic Myeloid Leukemia: Biology and Treatment
by Angelo M Carella (Editor), George Q Daley (Editor), Connie J. Eaves (Editor), John M Goldman (Editor), Hehlmann Rudiger (Editor)

In this volume, an international team of experts in chronic myeloid leukemia share their expertise. In particular, they contribute their insights on the latest advances in understanding this disease, and the implications those developments have for its management. They explore many topics, including a review of molecular and cellular biology, discussion of conventional chemotherapy and interferon therapy, and recent developments in allografting and autografting. The reader gains not only an incisive view of the biological structure of the disease, but applications of that biology to treatment modalities. Chronic Myeloid Leukemia is ideal for oncologists and other specialists in the field.